Member-led steering committees composed of global pharma and tech representatives will develop new project ideas to drive industry change

The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, has announced its four new strategic priorities, and has appointed steering committees to lead collaboration in these areas: Harness AI to Expedite R&D, Deliver Data-Driven Value, Sustainability Driven R&D and Accelerate Use of Real-World Data. The priorities were selected in response to the evolving needs of the life science industry amid digital transformation, climate change, and shifts in how research is conducted and healthcare is delivered post-pandemic. The Alliance consulted its members and revisited the challenges raised in its latest Lab of the Future survey. The steering committees are representative of the Pistoia Alliance’s global membership, including experts from top pharma and technology companies, and will help formulate the Alliance’s strategy and project goals.

“The life sciences industry is at an inflexion point in the face of technological innovation, global health challenges, and the emergence of new business models. The pandemic was a similar time of upheaval that proved the value of cross-industry collaboration, and researchers want this change to continue. In our recent survey, 60% of life science experts pointed to a need for collaboration or building industry best practice guides,” comments Dr Hall Gregg, Chief Portfolio Officer at the Pistoia Alliance. “Solving common issues has always been Pistoia’s mission – the time is right to realign our portfolio amid these tectonic shifts, so that we can focus on the issues that matter most to our members and industry. We now invite members to come forward to contribute to this strategy and suggest new project ideas under these four umbrellas.”

The Pistoia Alliance’s pre-competitive legal framework and established history of delivering tangible solutions for common industry barriers means it is well positioned to tackle global challenges. The new committees will build on the work the Alliance has been doing over the past 15 years and give members even more of a chance to steer the Alliance’s strategy. The priorities are:

• Harness AI to Accelerate R&D – 54% of life sciences companies already use AI in the lab, and 60% plan further investment in the technology in the next two years. But there are still common barriers to AI adoption, including ethical and privacy concerns, which this group will address through initiatives such as the AI Community of Experts.
• Deliver Data-Driven Value – Data is the foundation for emerging technologies like Generative AI, but the industry still struggles to manage, maintain, and share data effectively. This group aims to overcome these common challenges through projects that leverage ontologies, data enrichment, and data integration technologies.
• Sustainability driven R&D – ESG has become a priority for pharma, as the industry looks to reduce its carbon footprint and increase the diversity of its workforce. This group will look at the tangible changes the industry can make in these areas, for example the Carbon Footprint for Decentralized Trials project.
• Accelerate the use of Real-World Data – The rise of wearables, internet of things (IOT) devices, social media and electronic health records holds huge promise for collecting and sharing patient data and enabling them to be more involved in their care. But harnessing this data in an accurate and ethical way is new territory for the industry and must be explored together.

“External pressures are continually changing and technology is always progressing – so the Pistoia Alliance must evolve too. We designed these priorities to be ‘living and breathing’, so they can flex to the areas that will be most impactful for our members now and in the future,” comments Dr Becky Upton, President of the Pistoia Alliance. “We are confident that the new priorities will fuel even more breakthroughs. We encourage companies to come forward and support collaborative innovation through our new projects, so that we can bring new treatments to patients sooner – who are the most important stakeholders of all.”

About Pistoia Alliance

The Pistoia Alliance is a global, not-for-profit members’ organization made up of life science companies, technology and service providers, publishers, and academic groups working to lower barriers to innovation in life science and healthcare R&D. It was conceived in 2007 and incorporated in 2009 by representatives of AstraZeneca, GSK, Novartis, and Pfizer who met at a conference in Pistoia, Italy. Its projects transform R&D through pre-competitive collaboration. It overcomes common R&D obstacles by identifying the root causes, developing standards and best practices, sharing pre-competitive data and knowledge, and implementing technology pilots. There are currently over 200 member companies; members collaborate on projects that generate significant value for the worldwide life sciences R&D community, using the Pistoia Alliance’s proven framework for open innovation.